Workflow
上海昊海生物科技股份有限公司 关于公司核心技术人员离职的公告

Core Points - The company announces the departure of core technical personnel, Mr. Gan Renbao, due to age, and confirms that this will not impact the company's technology development or operations [1][5] - Mr. Gan has not participated in any ongoing projects and has completed the handover of his responsibilities [1][3] - The company has a stable research and development (R&D) team, with the number of R&D personnel remaining consistent over the years [5][7] Departure Details - Mr. Gan Renbao, born in 1939, has a background in biochemistry and cell biology, and has been with the company since July 2010 [1] - He has contributed to two patented inventions during his tenure, which are owned by the company, and there are no disputes regarding intellectual property rights [3][5] - As of the announcement date, Mr. Gan does not hold any shares in the company [2] Impact on the Company - The departure of Mr. Gan will not adversely affect the company's core technologies or competitive capabilities, as the existing R&D team is well-structured and capable [5][7] - The company has a total of 344, 366, and 350 R&D personnel projected for the end of 2022, 2023, and 2024 respectively, indicating a stable workforce [5] - The company emphasizes its commitment to R&D and has established a comprehensive project management system to ensure continuous innovation [7] Confidentiality Agreement - A confidentiality agreement is in place with Mr. Gan, ensuring that he will not disclose any company secrets post-departure [4] - There have been no indications of Mr. Gan joining a competitor or violating the confidentiality terms [4]